{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:34:50Z","timestamp":1789878890000,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.urolonc.2016.10.018","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T05:35:02Z","timestamp":1481348102000},"page":"112.e1-112.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are undergoing androgen deprivation and radiation therapies"],"prefix":"10.1016","volume":"35","author":[{"given":"Landon","family":"Wark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klonisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Awe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"LeClerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Quon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-2201","authenticated-orcid":false,"given":"Sabine","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.10.018_bib1","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2172::AID-CNCR16>3.0.CO;2-K","article-title":"Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate","volume":"83","author":"D\u05f3Amico","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.10.018_bib2","first-page":"1314","article-title":"Controversies in prostate cancer radiotherapy: consensus development","volume":"8","author":"Lukka","year":"2001","journal-title":"Can J Urol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer\u2014classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2016.10.018_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijrobp.2009.07.1724","article-title":"Evaluating the phoenix definition of biochemical failure after 125I prostate brachytherapy: can PSA kinetics distinguish PSA failures from PSA bounces?","volume":"78","author":"Thompson","year":"2010","journal-title":"Int J Radiat Oncol Biol Phy"},{"key":"10.1016\/j.urolonc.2016.10.018_bib6","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-05-0109","article-title":"Prostate cancer clinical trial end points: \u201cRECIST\u201ding a step backwards","volume":"11","author":"Scher","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib7","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1158\/1078-0432.CCR-07-0944","article-title":"Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study","volume":"14","author":"Berthold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib8","first-page":"146","article-title":"A case of cancer in which cells similar to those in the tumors were seen in the blood after death","volume":"14","author":"Ashworth","year":"1869","journal-title":"Aust Med J"},{"key":"10.1016\/j.urolonc.2016.10.018_bib9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0090-4295(02)02581-5","article-title":"RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy.","volume":"61","author":"Gewanter","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.10.018_bib10","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0022-5347(05)67621-5","article-title":"Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence","volume":"163","author":"Mejean","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2016.10.018_bib11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1078-0432.CCR-08-1754","article-title":"Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence","volume":"15","author":"Morgan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nature06385","article-title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","volume":"450","author":"Nagrath","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.10.018_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12094-012-0775-5","article-title":"Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy","volume":"14","author":"Lowes","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib14","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1158\/1078-0432.CCR-10-2650","article-title":"Circulating tumor cells as biomarkers in prostate cancer","volume":"17","author":"Danila","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib15","first-page":"1","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","author":"Smerage","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib16","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/annonc\/mdq030","article-title":"All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer","volume":"21","author":"Coumans","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib17","first-page":"427","article-title":"A new device for rapid isolation by size and characterization of rare circulating tumor cells","volume":"31","author":"Desitter","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib18","first-page":"479","article-title":"Circulating tumor cell isolation: the assets of filtration methods with polycarbonate track-etched filters.","volume":"27","author":"Dolfus","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.18632\/aging.100524","article-title":"Structural and functional association of androgen receptor with telomeres in prostate cancer cells","volume":"5","author":"Zhou","year":"2013","journal-title":"Aging"},{"key":"10.1016\/j.urolonc.2016.10.018_bib20","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1074\/jbc.M109.098798","article-title":"Androgen receptor interacts with telomeric proteins in prostate cancer cells","volume":"285","author":"Kim","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2016.10.018_bib21","first-page":"6405","article-title":"Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis","volume":"62","author":"Meeker","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7007-2-12","article-title":"The three-dimensional organization of telomeres in the nucleus of mammalian cells","volume":"2","author":"Chuang","year":"2004","journal-title":"BMC Biol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/jcb.20760","article-title":"The significance of telomeric aggregates in the interphase nuclei of tumor cells","volume":"97","author":"Mai","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.urolonc.2016.10.018_bib24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1593\/neo.91752","article-title":"Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients","volume":"12","author":"Gadji","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.urolonc.2016.10.018_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1593\/tlo.12142","article-title":"Three-dimensional telomere signatures of Hodgkin- and Reed-Sternberg Cells at diagnosis identify patients with poor response to conventional chemotherapy","volume":"5","author":"Knecht","year":"2012","journal-title":"Transl Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1593\/tlo.13613","article-title":"Three-dimensional nuclear telomere organization in multiple myeloma","volume":"6","author":"Klewes","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib27","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3390\/cancers5031086","article-title":"Dynamic length changes of telomeres and their nuclear organization in chronic myeloid leukemia","volume":"5","author":"Samassekou","year":"2013","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2016.10.018_bib28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4161\/cc.4.10.2082","article-title":"Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: C-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements","volume":"4","author":"Mai","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.urolonc.2016.10.018_bib29","doi-asserted-by":"crossref","first-page":"9613","DOI":"10.1073\/pnas.0407512102","article-title":"C-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus","volume":"102","author":"Louis","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2016.10.018_bib30","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/jcb.22501","article-title":"Initiation of telomere-mediated chromosomal rearrangements in cancer","volume":"109","author":"Mai","year":"2010","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.urolonc.2016.10.018_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/239362","article-title":"Benchtop technologies for circulating tumor cells separation based on biophysical properties","author":"Low","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.urolonc.2016.10.018_bib32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2818.2001.00949.x","article-title":"Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy","volume":"204","author":"Schaefer","year":"2001","journal-title":"J Microsc"},{"key":"10.1016\/j.urolonc.2016.10.018_bib33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cyto.a.20159","article-title":"Characterizing the three-dimensional organization of telomeres","volume":"6","author":"Vermolen","year":"2005","journal-title":"Cytometry"},{"key":"10.1016\/j.urolonc.2016.10.018_bib34","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/bjc.2015.332","article-title":"PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate Cancer patients","volume":"113","author":"Punnoose","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2016.10.018_bib35","first-page":"1","article-title":"High-risk prostate cancer: a disease of genomic instability","author":"Tapia-Laliena","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/pros.22997","article-title":"Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial","author":"Heaphy","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.10.018_bib37","series-title":"J Fluoresc","article-title":"In vitro culture and characterization of human lung cancer circulating tumor cells isolated by size exclusion from an orthotopic nude-mouse model expressing fluorescent protein","author":"Kolostova","year":"2014"},{"key":"10.1016\/j.urolonc.2016.10.018_bib38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/pros.22625","article-title":"Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer","volume":"73","author":"Chen","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2016.10.018_bib39","first-page":"461","article-title":"Circulating tumor cells isolation: the \u201cpost-EpCAM Era\u201d","volume":"27","author":"Raimondi","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1373\/clinchem.2015.242537","article-title":"Functional studies on viable circulating tumor cells","volume":"62","author":"Pantel","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.urolonc.2016.10.018_bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.canlet.2008.12.007","article-title":"Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer","volume":"277","author":"Paris","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.urolonc.2016.10.018_bib42","series-title":"Critical Rev Clin Lab Sci","first-page":"1","article-title":"Using circulating tumor cells to inform on prostate cancer biology and clinical utility","author":"Li","year":"2015"},{"key":"10.1016\/j.urolonc.2016.10.018_bib43","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-014-1775-3","article-title":"Circulating tumor cell detection in high-risk non-metastatic prostate cancer","author":"Loh","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib44","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel with or without Atrasentan for Metastatic Castration-Resistant Prostate Cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2016.10.018_bib45","first-page":"1","article-title":"Circulating tumor cells in biochemical recurrence of prostate cancer","author":"Aragon-Ching","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2016.10.018_bib46","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.55.3487","article-title":"Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer","volume":"33","author":"Scher","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2016.10.018_bib47","first-page":"6705","article-title":"Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer","volume":"34","author":"Okegawa","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00432-013-1377-5","article-title":"Detection of circulating tumor cells in different stages of prostate cancer","volume":"139","author":"Thalgott","year":"2013","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000356251","article-title":"Prevalence of circulating tumor cells in localized prostate cancer","volume":"7","author":"Khurana","year":"2013","journal-title":"Curr Urol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.12.003","article-title":"Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer","author":"Meyer","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib51","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2016.10.018_bib52","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.1158\/0008-5472.CAN-09-0801","article-title":"Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model.","volume":"69","author":"Helzer","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib53","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1158\/1078-0432.CCR-12-0087","article-title":"Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.\u201d","volume":"18","author":"Gadji","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.018_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1593\/tlo.12361","article-title":"Three-dimensional telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations","volume":"6","author":"Adebayo Awe","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib55","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cyto.a.21012","article-title":"Novel automated three-dimensional genome scanning based on the nuclear architecture of telomeres","volume":"79","author":"Klewes","year":"2011","journal-title":"Cytometry A\u202f"},{"key":"10.1016\/j.urolonc.2016.10.018_bib56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/thy.2013.0118","article-title":"Three-dimensional telomere dynamics in follicular thyroid cancer.","volume":"24","author":"Wark","year":"2014","journal-title":"Thyroid\u202f"},{"key":"10.1016\/j.urolonc.2016.10.018_bib57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrurol.2015.50","article-title":"Synergistic action of image-guided radiotherapy and androgen deprivation therapy","volume":"12","author":"Locke","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2016.10.018_bib58","article-title":"Canadian Cancer Statistics 2010","author":"Canadian Cancer Society\u2019s Steering Committee","year":"2010","journal-title":"Statistics"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916303325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916303325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:56Z","timestamp":1761041396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916303325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1078143916303325"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.10.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are undergoing androgen deprivation and radiation therapies","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}